Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
Phase 2
Not yet recruiting
- Conditions
- Asthma
- Interventions
- Drug: placeboDrug: 610 100mgDrug: 610 300mg
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2022-09-06
- Target Recruit Count
- 120
- Registration Number
- NCT05528679
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
Phase 3
Recruiting
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Drug: 601 1.25mg
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 350
- Registration Number
- NCT05520177
- Locations
- 🇨🇳
BeiJing Hospital, BeiJing, Beijing, China
🇨🇳The First Affiliated Hospital of JiNan University, GuangZhou, Guangdong, China
🇨🇳HeNan Provincial Eye Hospital, ZhengZhou, Henan, China
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
Phase 2
Not yet recruiting
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Drug: Recombinant anti-PD-1 humanized monoclonal antibody injection
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Target Recruit Count
- 30
- Registration Number
- NCT05193214
- Locations
- 🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-06
- Target Recruit Count
- 162
- Registration Number
- NCT05145179
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Phase 2
Not yet recruiting
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2021-11-30
- Target Recruit Count
- 70
- Registration Number
- NCT05138146
- Locations
- 🇨🇳
Beijing ji shui tan Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
Phase 1
- Conditions
- Periodic Fever SyndromeSystemic Juvenile Idiopathic Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2021-08-30
- Target Recruit Count
- 34
- Registration Number
- NCT05027373
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
Phase 2
- Conditions
- Pathological Myopic Choroidal Neovascularization
- Interventions
- Drug: 601
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT04922151
- Locations
- 🇨🇳
Peking Union Medical College Hospital, BeiJing, China
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Phase 2
Completed
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Drug: 601 1.25mgDrug: Ranibizuman 0.5 mg
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 60
- Registration Number
- NCT04667910
- Locations
- 🇨🇳
TianJing Medical University Eye Hospital, TianJing, TianJing, China
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
Phase 2
Completed
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Drug: 601 1.25mgDrug: Ranibizuman 0.5 mg
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 60
- Registration Number
- NCT04667897
- Locations
- 🇨🇳
BeiJing Hospital, BeiJing, Beijing, China
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-11-10
- Target Recruit Count
- 40
- Registration Number
- NCT04527718
- Locations
- 🇺🇸
Covance Dallas Clinical Research Unit, Dallas, Texas, United States